University of Hertfordshire

C2 by-pass: Cross-talk between the complement classical and alternative pathways

Research output: Contribution to journalArticlepeer-review

  • A Laich
  • H Patel
  • A Zarantonello
  • R B Sim
  • J M Inal
View graph of relations
Original languageEnglish
Article number152225
Number of pages9
JournalImmunobiology
Volume227
Issue3
Early online date5 May 2022
Publication statusPublished - 31 May 2022

Abstract

Several disorders associated with the total or partial absence of components of the human complement system are known. Deficiencies of classical pathway (CP) components are generally linked to systemic lupus erythematosus (SLE) or SLE-like syndromes. However, only approximately one-third of patients who lack C2 show mild symptoms of SLE. The relatively high frequency of homozygous C2 deficiency without or with minor disease manifestation suggests that there might be a compensatory mechanism which allows the activation of the CP of complement without the absolute requirement of C2. In this study we show that factor B (FB), the C2 homologue of the alternative pathway (AP) of complement, can substitute for C2. This was confirmed by using C4b as immobilised ligand and FB as analyte in Surface Plasmon Resonance (BIACORE). C2 binding to the immobilised C3b-like molecule C3(CH 3NH 2) was not seen. The estimated binding constant for C4bB complex formation was 2.00 * 10 -5 [M]. We were further able to demonstrate that C4b supports the cleavage of Factor B by Factor D. Finally, cleavage of 125I-C3 by C4bBb was evaluated and gave strong evidence that the "hybrid" convertase C4bBb can cleave and activate C3 in vitro. Cleavage activity is very low, but consistent with some of the "C2-bypass" observations of others.

Notes

© 2022 Elsevier GmbH. All rights reserved.

ID: 31714356